Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, secures a spot on Fortune's 2025 list of the 100 Most ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into mult | ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Q2 2025 Management View CEO Reshma Kewalramani highlighted "very strong performance across the board, growing and diversifying revenue with multiple new product launches," noting $2.96 billion in ...

Vertex stock crashed late Monday after the company said it wouldn't advance a next-generation pain drug into more testing.

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...

The experimental drug is similar to the Boston-based company’s recently approved pill Journavx but could potentially be given ...

Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and ...

Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...